Physician profile
Grace Chen
NPI 1366866493
$2,987.96
in general payments reported to CMS, 2019-2025
27 companies · $797 in 2025
The $797 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $577 · 2023: $535 · 2024: $731 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $422.15 | 2022-2025 | Verquvo, Belsomra |
| Genzyme Corporation | $399.87 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $380.03 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.02 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $220.31 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $129.99 | 2024-2025 | Opsumit |
| Scpharmaceuticals INC. | $101.04 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Edwards Lifesciences Corporation | $92.82 | 2023-2025 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $89.32 | 2024-2025 | Zoryve |
| Amgen INC. | $86.79 | 2022-2025 | Repatha, Evenity, Prolia |
| Janssen Biotech, INC. | $78.52 | 2023-2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $70.41 | 2024-2025 | Farxiga |
| Pfizer INC. | $65.72 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.66 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.27 | 2025 | |
| Ardelyx, INC. | $52.04 | 2024-2025 | Ibsrela |
| Acadia Pharmaceuticals INC | $50.71 | 2025 | Nuplazid |
| Amarin Pharma, INC. | $45.98 | 2022 | |
| Sumitomo Pharma America, INC. | $43.78 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $36.50 | 2025 | Nexletol |
| Verona Pharma, INC. | $35.67 | 2025 | Ohtuvayre |
| Heartflow, INC. | $35.54 | 2024-2025 | |
| Boston Scientific Corporation | $33.05 | 2024 | Watchman Flx |
| Arcutis Biotherapeutics, INC. | $24.56 | 2025 | Zoryve |
| Eisai INC. | $21.29 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.